# Biological Insights of First Relapsed-refractory Patients With Mantle Cell Lymphoma: the MANTLE-FIRST BIO Study.

> **NCT04882475** · — · ACTIVE_NOT_RECRUITING · sponsor: **Fondazione Italiana Linfomi - ETS** · enrollment: 160 (actual)

## Conditions studied

- Mantle Cell Lymphoma

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT04882475
- **Lead sponsor:** Fondazione Italiana Linfomi - ETS
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-02-08
- **Primary completion:** 2026-04
- **Final completion:** 2026-04
- **Target enrollment:** 160 (ACTUAL)
- **Last updated:** 2026-01-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04882475

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04882475, "Biological Insights of First Relapsed-refractory Patients With Mantle Cell Lymphoma: the MANTLE-FIRST BIO Study.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04882475. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*